Invivyd, Inc. (IVVD) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 5, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Invivyd, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Invivyd, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-25.29%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Invivyd, Inc. actually do?
Answer:
Invivyd, Inc. is a biopharmaceutical company focused on developing monoclonal antibody (mAb) therapies for serious viral infectious diseases, starting with COVID-19 and expanding into indications like RSV and measles. Its lead product, PEMGARDA(R) (pemivibart), received emergency use authorization (EUA) from the FDA in March 2024 for pre-exposure prophylaxis in immunocompromised individuals. The company is advancing VYD2311, a next-generation COVID-19 mAb candidate, through Phase 3 clinical trials, with a compact pathway to potential BLA approval. Invivyd leverages its proprietary technology platform and partnerships, including with Adimab, to discover, engineer, and optimize antibodies, aiming to deliver continuous pharmaceutical activity against evolving viral threats. The company relies on third-party contract manufacturers for its product candidates and has a direct sales force for commercialization in the U.S.
Question:
What are Invivyd, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by sales of PEMGARDA in the U.S. The company expects future revenue from VYD2311 and other pipeline candidates.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required